person · Reporting owner
Martins Eduardo Bruno
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | SVP, Liver and Infectious Dise | March 09, 2017 | March 14, 2017 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Chief Medical Officer | February 19, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 09, 2017 · Filed March 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.75 · Expires 2027-03-09 | Direct | 30,000 |
Reported balance
After 2017-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date.
Sagimet Biosciences Inc.
Report date February 19, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Common StockSEC Table I · non-derivative | Direct | 147,296 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 44,000 · Balance 147,296 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2036-02-18 | Direct | 88,000 |
Reported balance
After 2026-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-19 · Grant · Acquired 88,000 · Balance 88,000 F2: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.
F2: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 20, 2026 16:42 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 88,000 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001104659-26-018194 · tm266959-3_4seq1.xml · derivative · entry 2 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 Underlying: Series A Common Stock · 88,000 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 16:42 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-018194 · tm266959-3_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,296 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:06 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 3,640 | $5.36 | $19,511.13 |
DisclosureSEC source: 0001104659-26-014272 · tm266207-2_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,296 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 16:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 8,277 | $9.13 | $75,607.08 |
DisclosureSEC source: 0001104659-25-070015 · tm2521574-2_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,936 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 16:44 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 138,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001104659-25-010589 · tm255919-4_4seq1.xml · derivative · entry 2 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,000 Underlying: Series A Common Stock · 138,000 shares Expires 2035-02-05 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 16:44 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-010589 · tm255919-4_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,213 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 16:06 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 8,357 | $3.10 | $25,910.04 |
DisclosureSEC source: 0001104659-24-081892 · tm2420000-3_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,213 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 16:23 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 89,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-120375 · tm2331048-3_4seq1.xml · nonDerivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,570 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 16:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 44,009 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082727 · tm2321276-17_4seq1.xml · derivative · entry 4 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,009 Underlying: Series A Common Stock · 44,009 shares Expires 2033-04-19 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 16:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,009 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082727 · tm2321276-17_4seq1.xml · derivative · entry 3 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,009 shares Expires 2033-04-19 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 16:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 198,132 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082727 · tm2321276-17_4seq1.xml · derivative · entry 2 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,132 Underlying: Series A Common Stock · 198,132 shares Expires 2031-02-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 16:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 198,132 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082727 · tm2321276-17_4seq1.xml · derivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 198,132 shares Expires 2031-02-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 19:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001209191-17-020648 · doc4.xml · derivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · SVP, Liver and Infectious Dise 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-03-09 F1 · derivative.exercise_date: The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 23, 2016 Filed Sep 15, 2016 14:54 UTC Amendment | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 65,216 | $0.00 Strike: $15.89 | $0.00 |
DisclosureSEC source: 0001209191-16-141546 · doc4a.xml · derivative · entry 1 Martins Eduardo Bruno · CIK 0001670431 · SVP, Liver and Infectious Dise 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,216 Underlying: Common Stock · 65,216 shares Expires 2026-03-23 F1 · derivative.exercise_date: The option will vest as to 25% of the option shares on November 1, 2016 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date. F2 · derivative.exercise_date: The option grant was approved by Issuer's board of directors on March 22, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.